Analyst Consensus ?
1 unmapped firm rating excluded from the percentages.
Generac Holdings Inc. · GNRC · FY2026 Q1 · Calendar Q2 2026
Generac's Q1 FY2026 results mark a clear inflection from the prior quarter's soft residential demand. The 12% YoY revenue recovery, 28% C&I surge, and 35% EPS beat reflect data-center generator demand materializing faster than expected, reinforced by the Enercon acquisition and a non-binding $600M hyperscale notice to proceed. With backlog now over $700M, management has raised full-year guidance for both sales and adjusted EBITDA margins. The stock's 16.5% abnormal move on the report and subsequent 10.5% drift suggest the market is repricing the data-center growth narrative. At $196, the stock trades at a roughly 52% discount to the consensus target of $298.
Generac Holdings Inc. specializes in the engineering, manufacturing, and global distribution of diverse power generation systems, energy storage solutions, and related electrical products. The company caters to residential users, light commercial enterprises, and industrial sectors worldwide. At its core, Generac produces vital components such as engines, alternators, batteries, advanced electronic controls, and robust steel enclosures. For homeowners, the company provides a range of automatic standby generators, from 7.5kW up to 150kW, including air-cooled models (7.5kW-26kW) and more powerful liquid-cooled units (22kW-150kW). Many of these residential systems are compatible with Mobile Link, a remote monitoring platform. Generac also offers portable generators, spanning outputs from 800W to 17.5kW, alongside an extensive catalog of outdoor power equipment like trimmers, mowers, log splitters, and pressure washers.…
1 unmapped firm rating excluded from the percentages.
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Stifel | Buy | Buy | Maintain | Jul 30, 2026 |
| Needham | Buy | Buy | Maintain | Jul 30, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Jul 30, 2026 |
| Canaccord Genuity | Buy | Buy | Maintain | Jul 30, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 30, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Jul 2, 2026 |
| UBS | Buy | Buy | Maintain | Jun 11, 2026 |
| Jefferies | Buy | Hold | Upgrade | May 22, 2026 |
| Stephens & Co. | Overweight | Overweight | Maintain | May 21, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | May 1, 2026 |
| TD Cowen | Buy | Buy | Maintain | Apr 30, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Apr 30, 2026 |
| Argus Research | Buy | Buy | Maintain | Apr 30, 2026 |
| B of A Securities | Buy | Buy | Maintain | Mar 26, 2026 |
| Guggenheim | Neutral | Buy | Downgrade | Feb 12, 2026 |
| Baird | Outperform | Neutral | Upgrade | Jan 9, 2026 |
| Roth Capital | Neutral | Neutral | Maintain | Jul 22, 2025 |
| TD Securities | Buy | Buy | Maintain | May 1, 2025 |
| Piper Sandler | Overweight | Overweight | Maintain | Apr 17, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Feb 13, 2025 |
| Truist Securities | Buy | Buy | Maintain | Jan 16, 2025 |
| Roth MKM | Neutral | Neutral | Maintain | Oct 22, 2024 |
| Northland Capital Markets | Outperform | Outperform | Maintain | Aug 1, 2024 |
| Scotiabank | Sector Perform | Sector Perform | Maintain | Jul 29, 2024 |
| Janney Montgomery Scott | Neutral | Buy | Downgrade | Jun 13, 2024 |
| Oppenheimer | Outperform | Outperform | Maintain | May 2, 2024 |
| OTR Global | Positive | Mixed | Upgrade | Apr 2, 2024 |
| William Blair | Outperform | Outperform | Maintain | Jul 6, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Feb 2, 2023 |
| Keybanc | Overweight | Downgrade | Oct 20, 2022 | |
| Cowen & Co. | Outperform | Outperform | Maintain | Sep 30, 2022 |
| Colliers Securities | Buy | Buy | Maintain | Dec 15, 2021 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | Feb 12, 2021 |
| Bank of America | Neutral | Buy | Downgrade | Nov 1, 2019 |
| Northcoast Research | Buy | Neutral | Upgrade | May 3, 2019 |
| Stifel Nicolaus | Hold | Hold | Maintain | Aug 2, 2018 |
| SunTrust Robinson Humphrey | Buy | Hold | Upgrade | Feb 14, 2018 |
| Wolfe Research | Perform | Peer Perform | Maintain | Jul 11, 2017 |
| BMO Capital | Outperform | Outperform | Maintain | Nov 12, 2012 |
Upside is calculated against the persisted current price $196.77. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Roth Capital | Analyst unavailable | $214 | $192.3 | +8.8% | Jul 30, 2026 |
| D.A. Davidson | Analyst unavailable | $333 | $192.85 | +69.2% | Jul 30, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $333 | $196.07 | +69.2% | Jul 30, 2026 |
| Robert W. Baird | Analyst unavailable | $305 | $191.26 | +55.0% | Jul 30, 2026 |
| Needham | Analyst unavailable | $283 | $195.19 | +43.8% | Jul 30, 2026 |
| Stifel Nicolaus | Stephen Gengaro | $285 | $195.19 | +44.8% | Jul 30, 2026 |
| Barclays | Analyst unavailable | $278 | $195.19 | +41.3% | Jul 30, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $325 | $215.61 | +65.2% | Jul 22, 2026 |
| Barclays | Analyst unavailable | $285 | $278.62 | +44.8% | Jun 29, 2026 |
| UBS | Analyst unavailable | $335 | $239.11 | +70.2% | Jun 11, 2026 |
| Jefferies | Analyst unavailable | $302 | $247.79 | +53.5% | May 22, 2026 |
| Raymond James | Tanner James | $302 | $247.79 | +53.5% | May 22, 2026 |
| UBS | Analyst unavailable | $305 | $263 | +55.0% | May 5, 2026 |
| Stephens | Analyst unavailable | $290 | $257 | +47.4% | May 1, 2026 |
| Roth Capital | Chip Moore | $257 | $254.23 | +30.6% | Apr 30, 2026 |
| Argus Research | John Eade | $290 | $257.78 | +47.4% | Apr 30, 2026 |
| Stifel Nicolaus | Analyst unavailable | $275 | $256.29 | +39.8% | Apr 30, 2026 |
| Canaccord Genuity | Analyst unavailable | $325 | $252.92 | +65.2% | Apr 30, 2026 |
| Robert W. Baird | Analyst unavailable | $311 | $252.92 | +58.1% | Apr 30, 2026 |
| Barclays | Christine Cho | $228 | $194.4 | +15.9% | Mar 27, 2026 |
| UBS | Jon Windham | $270 | $215.04 | +37.2% | Feb 13, 2026 |
| Barclays | Analyst unavailable | $213 | $223.72 | +8.2% | Feb 12, 2026 |
| Stifel Nicolaus | Analyst unavailable | $235 | $221.67 | +19.4% | Feb 12, 2026 |
| Roth Capital | Analyst unavailable | $220 | $214.99 | +11.8% | Feb 12, 2026 |
| Robert W. Baird | Michael Halloran | $292 | $214.99 | +48.4% | Feb 12, 2026 |
| Canaccord Genuity | Analyst unavailable | $275 | $214.99 | +39.8% | Feb 12, 2026 |
| Barclays | Analyst unavailable | $186 | $160.85 | -5.5% | Jan 20, 2026 |
| Canaccord Genuity | Analyst unavailable | $236 | $156.6 | +19.9% | Jan 13, 2026 |
| Robert W. Baird | Analyst unavailable | $199 | $148.79 | +1.1% | Jan 9, 2026 |
| Wells Fargo | Analyst unavailable | $195 | $136.99 | -0.9% | Dec 19, 2025 |
| Barclays | Analyst unavailable | $197 | $165.78 | +0.1% | Oct 31, 2025 |
| UBS | Analyst unavailable | $215 | $174.3 | +9.3% | Oct 30, 2025 |
| Roth Capital | Chip Moore | $184 | $180.86 | -6.5% | Oct 30, 2025 |
| Needham | Analyst unavailable | $248 | $183.96 | +26.0% | Oct 22, 2025 |
| Guggenheim | Analyst unavailable | $202 | $168.3 | +2.7% | Oct 9, 2025 |
| Barclays | Analyst unavailable | $188 | $165.67 | -4.5% | Oct 6, 2025 |
| Canaccord Genuity | Analyst unavailable | $240 | $164.26 | +22.0% | Sep 25, 2025 |
| UBS | Jon Windham | $220 | $181 | +11.8% | Jul 31, 2025 |
| Barclays | Analyst unavailable | $200 | $181 | +1.6% | Jul 30, 2025 |
| Stifel Nicolaus | Stephen Gengaro | $175 | $165.55 | -11.1% | Oct 31, 2024 |
| Truist Financial | Jordan Levy | $210 | $165.55 | +6.7% | Oct 31, 2024 |
| Goldman Sachs | Jerry Revich | $148 | $165.55 | -24.8% | Oct 31, 2024 |
| Citigroup | Vikram Bagri | $172 | $166.65 | -12.6% | Oct 21, 2024 |
| Piper Sandler | Kashy Harrison | $175 | $146.24 | -11.1% | Sep 24, 2024 |
| Canaccord Genuity | George Gianarikas | $200 | $155.68 | +1.6% | Aug 1, 2024 |
| Truist Financial | Jordan Levy | $170 | $147.8 | -13.6% | May 23, 2024 |
| Oppenheimer | Christopher Glynn | $145 | $127.63 | -26.3% | May 2, 2024 |
| Roth Capital | Chip Moore | $135 | $134.12 | -31.4% | Apr 23, 2024 |
| Canaccord Genuity | George Giankarikas | $150 | $131.34 | -23.8% | Apr 5, 2024 |
| CFRA | Strong Buy | $145 | $125.8 | -26.3% | Feb 7, 2024 |
| Truist Financial | Jordan Levy | $160 | $113.95 | -18.7% | Aug 4, 2023 |
| Canaccord Genuity | George Giankarikas | $175 | $135.54 | -11.1% | Feb 16, 2023 |
| Janney Montgomery | Sean Milligan | $160 | $91.15 | -18.7% | Dec 28, 2022 |
| Roth Capital | Philip Shen | $75 | $110.3 | -61.9% | Oct 20, 2022 |
| Piper Sandler | Kashy Harrison | $305 | $249.79 | +55.0% | Jul 21, 2022 |
| Wells Fargo | Praneeth Satish | $285 | $213.05 | +44.8% | Jun 29, 2022 |
| J.P. Morgan | Mark Strouse | $455 | $259.5 | +131.2% | May 5, 2022 |
| J.P. Morgan | Mark Strouse | $469 | $316.44 | +138.3% | Feb 16, 2022 |
| Bank of America Securities | Ross Gilardi | $350 | $265.19 | +77.9% | Jan 26, 2022 |
| Truist Financial | Tristan Richardson | $425 | $286.19 | +116.0% | Jan 24, 2022 |
| UBS | Jon Windham | $480 | $323.73 | +143.9% | Jan 10, 2022 |
| Piper Sandler | Kashy Harrison | $481 | $316.55 | +144.4% | Jan 7, 2022 |
| Roth Capital | Philip Shen | $555 | $453.4 | +182.1% | Nov 3, 2021 |
| Guggenheim | Joseph Osha | $460 | $409.19 | +133.8% | Jun 28, 2021 |
Track every rating change on GNRC the moment it posts. Free to start.
Start freeFollow GNRC with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeQ1 net sales rose 12% YoY to $1.06B, recovering from Q4's 12% decline. C&I sales jumped 28% (vs. 10% in Q4), led by data-center megawatt-generator demand and the Allmand and Enercon acquisitions. Residential standby sales were flat, but EBITDA margins expanded 500bps from the Generac Home re-organization and pricing after winter storm Fern. Backlog grew to over $700M, including a non-binding $600M notice to proceed from a hyperscale customer for 2027 deliveries. EPS of $1.80 beat the $1.33 estimate by 35.3%. Revenue narrowly topped the $1.05B consensus. Management tone was confident and guidance sentiment was raised, consistent with the prior quarter's direction but at a materially faster growth rate.
Management raised full-year 2026 net sales and adjusted EBITDA margin guidance. C&I sales are now expected to grow in the mid-to-high 20% range, accelerating from the prior 10% YoY pace. Residential growth remains projected in the mid-teens for 2026. Capex outlook is increasing, driven by the new Sussex, Wisconsin facility (production starting H2 2026) and continued investment in the Nebraska plant.
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.